(3R)-1-methyl-N-(2-methylpropyl)pyrrolidin-3-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (3R)-1-methyl-N-(2-methylpropyl)pyrrolidin-3-amine
• 化学式: C₉H₂₀N₂
• 分子量: 156.27
• InChiKey: HNMHXBYSUXFPRP-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• ANTIBACTERIAL COMPOUNDS
  申请人：Forge Therapeutics, Inc.

  公开号：US20210221796A1

  公开（公告）日：2021-07-22

  Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram-negative bacteria. Furthermore, the subject compounds and compositions are useful for the treatment of bacterial infection, such as urinary tract infection and the like.

  本文提供的是杂环衍生物化合物和包含这些化合物的药物组合物，其对抑制革兰氏阴性菌的生长非常有用。此外，这些化合物和组合物还可用于治疗细菌感染，如尿路感染等。
• SPIRO-CONDENSED INDOLE COMPOUNDS AS EHMT2 INHIBITORS
  申请人：Epizyme Inc

  公开号：EP4105203A1

  公开（公告）日：2022-12-21

  The present disclosure relates to substituted fused bi- or tri- heterocyclic compounds of formula (Va) to (Vf). The present disclosure also relates to pharmaceutical compositions containing these compounds. Said compounds are for use in methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2.

  本公开涉及式（Va）至（Vf）的取代融合二或三杂环化合物。本公开还涉及含有这些化合物的药物组合物。所述化合物用于通过抑制选自 EHMT1 和 EHMT2 的甲基转移酶来治疗疾病（例如镰状细胞贫血）的方法。
• COMBINATION THERAPIES WITH EHMT2 INHIBITORS
  申请人：Epizyme, Inc.

  公开号：US20200054635A1

  公开（公告）日：2020-02-20

  The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
• [EN] SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS<br/>[FR] COMPOSÉS BI-OU TRI-HÉTÉROCYCLIQUES FUSIONNÉS SUBSTITUÉS EN TANT QU'INHIBITEURS DE L'EHMT2
  申请人：EPIZYME INC

  公开号：WO2018064557A1

  公开（公告）日：2018-04-05

  The present disclosure relates to substituted fused bi- or tri- heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering a substituted fused bi- or tri- heterocyclic compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
• [EN] ANTIBACTERIAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIBACTÉRIENS
  申请人：FORGE THERAPEUTICS INC

  公开号：WO2020061375A1

  公开（公告）日：2020-03-26

  Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram -negative bacteria. Furthermore, the subject compounds and compositions are useful for the treatment of bacterial infection, such as urinary tract infection and the like.